SCHEMBL2746949

SCHEMBL2746949

COC(=O)c1ccc(N(Cc2ccccc2)Cc2ccccc2)c2cc(OCc3ccccc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.48
ALDH1A1 P00352 2/20 0.45
ALOX5 P09917 3/20 0.44
TSPO P30536 2/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PTGES O14684 1/20 0.43
MAOA P21397 2/20 0.43
ACHE P22303 2/20 0.43
PLA2G2A P14555 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5753078 0.96 MAOB (0.45) MAOBALDH1A1ALOX5TSPOPTGS1
SCHEMBL2747987 0.89 SMN1; SMN2 (0.50) MAOBALDH1A1ALOX5TSPOPTGS1
SCHEMBL28316742 0.83 LMNA (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL10029338 0.80 TSHR (0.52) MEN1KMT2AACHEPLA2G2ALMNA
SCHEMBL2747168 0.77 MAOB (0.46) MAOBALOX5NPC1RAB9AMEN1
SCHEMBL3962253 0.77 MAOB (0.61) MAOBALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL629952 0.77 MAOB (0.74) MAOBALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL22873361 0.76 MAOB (0.59) MAOBALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL22692220 0.76 MAOB (0.59) MAOBALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7881166 0.76 MAOB (0.59) MAOBALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET MAOB 902/4885ALDH1A1 81/4885ALOX5 627/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET MAOB 902/4885ALDH1A1 81/4885ALOX5 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.